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region. Figures for COPD prevalence vary from 3%
among Finnish women to 57% of Italians older than 45
years. Epidemiological research indicates that COPD is
an underdiagnosed and undertreated disease. The litera-
ture search for health economic articles generated 181
matching articles of which 26 analyses considered 
European health economics. Cost-of-illness and cost-
effectiveness studies were mainly used as analytic strate-
gies. Cost-of-illness studies indicate that hospital care and
medication are the major cost drivers in the treatment of
COPD. Annual direct expenditures per patient in Europe
range from €530 in France to €3239 in Spain. In cost-
effectiveness analyses, no uniformity in deﬁnition of out-
comes exist. Disease severity was not always delineated,
and the length of time horizon examined varied from 4
months to 2.5 years. CONCLUSION: Improvement of
diagnostic techniques and enforcement of professionalism
in diagnostic procedures as well as a uniform deﬁnition
of COPD have to be accomplished in order to obtain reli-
able epidemiological data and to ensure the quality of
health economics studies. These data could be used to
carry out health economics studies according to each
country´s guidelines or to develop them where no respec-
tive guidelines exist.
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OBJECTIVE: To elaborate a useful level of detail accord-
ing to measurement and valuation of costs associated
with rheumatoid arthritis. METHODS: Unit costs—com-
prehended as multiplicative part of costs as product of
amount and price—have a substantial impact on health
economic evaluations. Performing an intensive Internet
research we assessed country-speciﬁc unit costs for the 10
cost domains doctor visit, medication, diagnostic proce-
dures, monitoring, hospitalization, rehabilitation, per-
sonal help, stoppage, traveling and other treatments. The
most differentiated cost domains were rheumatic med-
ications (65 cost items) and monitoring (25 cost items).
We reported the type of cost item, country, total costs of
one unit, name of data source, date of data, homepage
address, date of review, calculation assumption and cal-
culation method. The evaluation was performed for Aus-
tralia, Canada, France, Germany, and Great Britain. All
unit costs were given in national currency as well as US$
for comparative purpose. RESULTS: Signiﬁcant differ-
ences in values of unit costs were identiﬁed with the Inter-
net research. The country-speciﬁc values of comparative
unit costs differed a lot. England and Australia show high
differences of unit cost values per type of doctor visit. All
ﬁve countries have high variances within the different
diagnostic procedures, the kind of personal help and the
type of traveling. The most differentiated references for
the evaluation of medication costs were found in
Germany. CONCLUSION: In general the identiﬁcation
of unit costs therefore has to adapt the speciﬁc payment
systems of health care. It is non-permissible to transfer
country-speciﬁc results to other countries. Because the
amount of unit costs differs a lot, each health economic
study report has to explain the used calculation approach.
Otherwise the user is unable to prove the robustness of
data. Additionally the performance of sensitivity analysis
is aggravated.
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OBJECTIVES: The German Agency for Health Technol-
ogy Assessment (DAHTA) at the German Institute for
Medical Documentation and Information (DIMDI) com-
missions research projects for Health Technology Assess-
ment (HTA). The authors were engaged to develop
methodological guidelines for the conduction of rapid
health economic HTA and simultaneously to conduct a
rapid health economic HTA to assess the cost-effective-
ness of Quantitative Ultrasound (QUS) as a technique for
screening and diagnosing osteoporosis. This abstract
describes ﬁrst experiences of the feasibility of the devel-
oped methodological guidelines made by the assessment
of cost-effectiveness of QUS. METHODS: Methodologi-
cal recommendations for rapid health economic HTA
were given to the following structural elements: study
question, background information, perspective, decision
analysis, searching and evaluation of information, dis-
cussion, conclusion, quality assurance and dissemination.
Based on this recommendations we conducted the assess-
ment of the cost-effectiveness of QUS. A detailed descrip-
tion of the guidelines as well as of the results of the
assessment of cost-effectiveness of QUS are given else-
where. RESULTS: Even though the methodological
guidelines turned out to be a proper instrument for the
conduction of rapid health economic HTA, two crucial
points should be pointed out: 1) study question should be
formulated precisely. We restricted the original study
question commissioned by DAHTA regarding to the
study population, number of compared technologies and
clinical outcome parameters; 2) methodological recom-
mendations clearly support the conduction of decision
modeling. In the case of QUS strong limitations could be
found, mainly due to the missing of effectiveness data.
CONCLUSION: The conduction of a rapid health eco-
nomic HTA demands careful considerations. In coopera-
tion with the potential addressee the study question
should be focused. In some cases, especially in the case a
decision analysis is demanded rapid health economic
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HTA will not be the appropriate instrument for its own,
but should be used in combination with comprehensive
HTA.
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The time inconsistency of decisions (TID) is the phenom-
enon, studied in various domains of economics, when a
decision is optimal from the perspective of one moment
in time and ceases being so in a subsequent moment.
OBJECTIVES: The aim of the study was to check for the
feasibility of prevailing of the TID in the pharmacoeco-
nomic sequential decision problems as well as to identify
the impact of this phenomenon on the process of decision
implementation and its outcomes. METHODS: A formal
model of sequential decision problems, both with and
without uncertainty, based on a graph theory, was pro-
vided. In such a framework the decision problem is rep-
resented by a graph and a set of functions over the vertices
representing the costs, effects and the probability distrib-
utions; decision alternatives are subgraphs; alternatives
are described by the expected values of costs and effects;
the rule of choice is to minimize criterion function of the
expected cost and effectiveness, representing the prefer-
ences of a decision maker. The ﬂow of time can be mod-
elled by analyzing subsequent decision problems, called
reduced problems, being the subgraphs of the original
problem obtained by cutting the original graph in a
certain vertex. RESULTS: There exist criteria susceptible
to TID phenomenon, in particular the cost-effectiveness
criterion is susceptible to TID in problems both with and
without uncertainty and cost-beneﬁt criterion or incre-
mental cost-effectiveness criterion are resistant to TID in
these kinds of problems. TID can lead actual decision
makers to behave differently than advised accordingly to
the model solutions and can make them choose actions
that lead to pareto-nonoptimal decisions. CONCLU-
SIONS: The TID is immanently present in pharmaco-
economic decision problems as the widely used
cost-effectiveness criterion is susceptible to it. It causes
ambiguities in decision problem solving as the actual deci-
sion maker(s) may not stick to the model solution in a
real life. The effect of this phenomenon can be pareto-
nonoptimal behaviour.
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OBJECTIVE: Hip fracture has long been associated with
signiﬁcantly increased morbidity as well as mortality. It is
argued that the currently available methodological guid-
ance on cost assessment falls short of distinguishing
between costs associated with a hip fracture and costs
associated with “old age”. METHODS: It is suggested
that additional insight into this question can be gained by
linking data on a patient’s resource consumption with his
or her outcomes data: In order to establish that costs were
directly attributable to the sustained hip fracture, they
needed to be accompanied by corresponding changes in
physical functioning, and changes in physical functioning
which the patient might associate with the sustained hip
fracture rather than “old age”. An analysis of the incre-
mental health and social care costs associated with 449
hip fractures in Tayside, Scotland (UK) in the year fol-
lowing the fracture suggests that in only a minority of
patients did long-term costs due to changes in accommo-
dation needs coincide with a decline in physical func-
tioning. RESULTS: Even fewer patients attributed any
changes that did occur in this respect to the sustained
fracture. Taking outcomes data into account thus reduced
the costs, which can be directly attributed to a hip frac-
ture by 40% in this patient group. CONCLUSIONS: The
data of this patient group thus appears to suggest that
cost estimates of hip fracture based on current method-
ologies of cost assessment are overestimating the real
costs of the condition by 40%.
METHODOLOGICAL ISSUES—Modeling
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OBJECTIVES: The few decision analytic models of glau-
coma treatment that exist have focused on absolute
reduction (in mmHg) of intraocular pressure (IOP) rather
than achievement of target IOP, which varies greatly 
by patient. We provide an overview of an innovative 
glaucoma model and highlight important modeling 
challenges. METHODS: A simulation model of the man-
agement of patients with open-angle glaucoma and/or
ocular hypertension was developed in Microsoft Excel.
The model examined competing strategies involving
sequential use of up to six interventions with switches
based on the monthly probability that a patient was “suc-
cessfully maintained” on therapy. These probabilities
were based on discontinuation data from actual clinical
practice. Therapy discontinuation could be due to lack of
IOP control, adverse events, or lack of compliance/
persistence. Outputs of the model include months of
treatment, switching frequency, days of IOP control, 
